BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the second quarter 2025, in conjunction with their partner Biogen's ...

Biogen (NASDAQ:BIIB) stock rises as Q2 2025 results surpass expectations, driven by Alzheimer's drug Leqembi developed with ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...

Biogen Inc. raised its full-year financial guidance as growing sales of its Alzheimer’s drug helped the biotech company beat ...

A month away from the PDUFA decision date for a Leqembi (lecanemab) subcutaneous autoinjector to be used for maintenance ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Because Leqembi is a Part B drug, not a more common Part D drug, many Medicare patients will owe 20 percent of the cost out-of-pocket. That adds up to more than $5,000 annually.

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Learn about Leqembi, Saudi Arabia's first approved treatment for Alzheimer’s disease, marking a major advancement in ...